Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Walvax Biotechnology Co., Ltd. (300142.SZ)
Kunming, CN
Walvax Biotechnology Co., Ltd. operates as a biological pharmaceutical enterprise, dedicated to the research, development, manufacturing, and commercialization of biopharmaceutical products within the Chinese market. Its product portfolio encompasses a range of biomedicines, notably vaccines, blood products, and other related treatments. A significant portion of Walvax's vaccine offerings addresses meningococcal diseases. This includes a Group A, C meningococcal polysaccharide conjugate vaccine for infants up to two years, which prevents conditions such as cerebrospinal meningitis and septicemia. For older children (above two years) and adults, they offer a Group A and C meningococcal polysaccharide vaccine, designed to protect against infections from Neisseria meningitidis serogroups A or C. Furthermore, the company provides a Group ACYW135 meningococcal polysaccharide vaccine, aimed at children over two years old, to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A, C, Y, and W135. Beyond meningococcal vaccines, the company supplies a Haemophilus influenzae type b conjugate vaccine, crucial for children aged two months to five years in preventing severe infectious diseases like meningitis, pneumonia, septicemia, cellulitis, arthritis, and epiglottitis. It also manufactures a combined diphtheria, tetanus, and acellular pertussis vaccine for individuals between three months and six years, safeguarding against these three infectious illnesses. Lastly, a 23-valent pneumococcal polysaccharide vaccine is offered for children over two years old, providing immunity against pneumococcal disease caused by 23 distinct serotypes. Established in 2001, Walvax Biotechnology Co., Ltd. maintains its headquarters in Kunming, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.16% | -7.01% | -1.00% | +4.13% | +5.84% | +17.97% | +24.59% | -55.25% | -81.66% | +15.32% | +14,200.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 1 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-14.6% Q1'26: -4.0% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+23.7% ★ Q1'26: +3,970.6% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-8.3% Q1'26: -25.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.9% Q1'26: +30.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+0.6% Q1'26: +5.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +2.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.89× ★ Q1'26: 2.58× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.01B
est: 1.05B (-4.2%)
|
668.26M
est: 692.00M (-3.4%)
|
874.32M
est: 878.00M (-0.4%)
|
1.12B
est: 1.09B (+2.7%)
|
2.94B
est: 4.06B (-27.6%)
|
3.46B
est: 3.70B (-6.4%)
|
5.09B
est: 5.53B (-8.1%)
|
4.11B
est: 3.38B (+21.7%)
|
2.82B
est: 2.86B (-1.2%)
|
2.41B
est: 2.49B (-3.3%)
|
2.53B
2.53B – 2.53B
+1.6% YoY
|
2.95B
2.95B – 2.95B
+16.3% YoY
|
3.31B
3.31B – 3.31B
+12.4% YoY
|
| EBITDA |
-161.58M
est: 283.05M (-157.1%)
|
16.40M
est: 186.56M (-91.2%)
|
241.87M
est: 236.70M (+2.2%)
|
248.11M
est: 294.40M (-15.7%)
|
1.15B
est: 1.09B (+4.9%)
|
927.65M
est: 997.09M (-7.0%)
|
1.42B
est: 1.49B (-4.7%)
|
1.12B
est: 782.18M (+43.3%)
|
387.61M
est: 660.81M (-41.3%)
|
481.71M
est: 576.70M (-16.5%)
|
586.09M
586.09M – 586.09M
+1.6% YoY
|
681.83M
681.83M – 681.83M
+16.3% YoY
|
766.39M
766.39M – 766.39M
+12.4% YoY
|
| EBIT |
-234.69M
est: 213.87M (-209.7%)
|
-93.01M
est: 140.96M (-166.0%)
|
126.15M
est: 178.85M (-29.5%)
|
171.48M
est: 222.44M (-22.9%)
|
1.02B
est: 827.00M (+23.8%)
|
792.22M
est: 753.38M (+5.2%)
|
1.17B
est: 1.13B (+4.1%)
|
831.05M
est: 472.53M (+75.9%)
|
24.01M
est: 399.21M (-94.0%)
|
69.96M
est: 348.40M (-79.9%)
|
354.07M
354.07M – 354.07M
+1.6% YoY
|
411.90M
411.90M – 411.90M
+16.3% YoY
|
462.99M
462.99M – 462.99M
+12.4% YoY
|
| Net Income |
-840.90M
est: 239.87M (-450.6%)
|
-537.14M
est: 47.97M (-1,219.7%)
|
1.05B
est: 118.33M (+784.1%)
|
141.97M
est: 159.91M (-11.2%)
|
1.00B
est: 986.12M (+1.7%)
|
427.75M
est: 604.99M (-29.3%)
|
728.65M
est: 1.02B (-28.2%)
|
419.39M
est: 134.67M (+211.4%)
|
142.16M
est: 279.89M (-49.2%)
|
177.74M
est: 175.93M (+1.0%)
|
287.88M
287.88M – 287.88M
+63.6% YoY
|
335.86M
335.86M – 335.86M
+16.7% YoY
|
399.84M
399.84M – 399.84M
+19.0% YoY
|
| SGA |
579.30M
est: 485.78M (+19.2%)
|
351.55M
est: 320.18M (+9.8%)
|
384.43M
est: 406.24M (-5.4%)
|
672.34M
est: 505.25M (+33.1%)
|
1.35B
est: 1.88B (-28.3%)
|
1.63B
est: 1.71B (-5.0%)
|
2.29B
est: 2.56B (-10.7%)
|
1.81B
est: 1.63B (+11.4%)
|
1.40B
est: 1.37B (+1.8%)
|
1.33B
est: 1.20B (+10.7%)
|
1.22B
1.22B – 1.22B
+1.6% YoY
|
1.42B
1.42B – 1.42B
+16.3% YoY
|
1.59B
1.59B – 1.59B
+12.4% YoY
|
| EPS |
-0.60
est: 0.15 (-500.0%)
|
-0.35
est: 0.03 (-1,266.7%)
|
0.68
est: 0.07 (+818.9%)
|
0.09
est: 0.10 (-7.7%)
|
0.65
est: 0.62 (+5.4%)
|
0.27
est: 0.38 (-28.6%)
|
0.46
est: 0.64 (-27.6%)
|
0.26
est: 0.08 (+208.8%)
|
0.09
est: 0.18 (-49.2%)
|
0.11
est: 0.11 (+0.0%)
|
0.18
0.18 – 0.18
+63.6% YoY
|
0.21
0.21 – 0.21
+16.7% YoY
|
0.25
0.25 – 0.25
+19.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-28 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-27 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-26 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-25 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-22 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-21 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-20 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-19 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-18 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 3/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Xtrackers Harvest CSI 500 China A-Shares Small Cap ETF ASHS | 0.20% | 73.2K | 0.65% |
| 2 | Xtrackers Harvest CSI A500 UCITS ETF 1D AH50.L | 0.06% | 10.4K | 0.65% |
| 3 | State Street SPDR S&P China ETF GXC | 0.02% | 72.4K | 0.59% |
| 4 | Xtrackers Emerging Markets Carbon Reduction and Climate Improvers ETF EMCR | 0.01% | 6.6K | 0.15% |
| 5 | Franklin FTSE China UCITS ETF FLXC.L | 0.01% | 164.3K | 0.19% |
| 6 | Franklin FTSE China ETF FLCH | 0.01% | 25.6K | 0.19% |
| 7 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 24.8K | 0.44% |
| 8 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 76.5K | 0.46% |
| 9 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.00% | 22.7K | 0.40% |
| 10 | State Street SPDR Portfolio Emerging Markets ETF SPEM | 0.00% | 582.1K | 0.07% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Changxiong Wu | Accounting Supervisor & CFO | — | male |
| Qingtang Duan | Engineering Director | — | male |
| Shaozhong Dong | Vice Chairman & Vice President | — | male |
| Wei Yao | President & Director | — | male |
| Yu Ran Liu | Vice President | — | male |
| Yun Yan Wu | Director of Operations | — | female |
| Yunchun Li | Chairman & Acting Secretary | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300142.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
